3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Melanoma
5
Neoplasms
3
Leukemia, Myeloid, Acute
3
Ovarian Neoplasms
2
Wilms Tumor
1
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Leukemia
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinogenesis
1
Interventions
Sorafenib
52
pembrolizumab
26
Nivolumab
20
Bevacizumab
19
Radiosurgery
17
Doxorubicin
12
atezolizumab
9
Erlotinib Hydrochloride
9
lenvatinib
8
cabozantinib
7
Magnetic Resonance Spectroscopy
7
tremelimumab
6
durvalumab
6
Ramucirumab
6
Radiofrequency Ablation
6
Cisplatin
6
Sunitinib
5
tislelizumab
4
regorafenib
4
Oxaliplatin
4
Leucovorin
4
Ipilimumab
4
Fluorouracil
4
Everolimus
4
Capecitabine
4
nintedanib
3
fluoromisonidazole
3
carotuximab
3
bavituximab
3
Tomography, X-Ray Computed
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma, Hepatocellular
×
Monatide (IMS 3015)
×
Clear all
No trials found.